Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.
The FDA asked, and Eli Lilly and Company delivered. The company now hopes to secure an additional approval for orforglipron/Foundayo that covers the treatment of type 2 diabetes.
Of all lawsuits filed against patients in 2024 in one U.S. state, physician practices and other non-hospital healthcare entities accounted for 80% of cases. That’s a complete inversion from just six years prior.
In the three or so years since it burst into healthcare, ambient AI scribe technology has run away with the win in the market-uptake race. What has been the return on investment in all those software packages?
Allie, a 37-year-old bottlenose dolphin, is reportedly in her second trimester of pregnancy and is giving researchers a unique opportunity to study the gestational period in dolphins.
The first patient has been enrolled in a new study of an optimized lead for LBBAP, an area with an explosion of interest in EP as a way to improve patient outcomes.
An advanced algorithm was trained to evaluate more than 100 different details about the inside of a patient's eye. Its ability to identify high-risk patients was comparable to more traditional techniques, exciting researchers.
When appropriately applied in critical care settings, AI can deliver considerable value to clinical staff, hospital management and local communities. In the process the technology may help resolve persistent staffing shortages.
Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
